Erste Asset Management GmbH Invests $708,000 in Autolus Therapeutics plc (NASDAQ:AUTL)

Erste Asset Management GmbH bought a new stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 195,000 shares of the company's stock, valued at approximately $708,000. Erste Asset Management GmbH owned approximately 0.07% of Autolus Therapeutics at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. B. Riley Wealth Advisors Inc. acquired a new stake in Autolus Therapeutics in the first quarter valued at $108,000. Cetera Advisors LLC acquired a new stake in shares of Autolus Therapeutics during the 1st quarter worth about $839,000. SG Americas Securities LLC lifted its stake in shares of Autolus Therapeutics by 853.2% during the 2nd quarter. SG Americas Securities LLC now owns 189,240 shares of the company's stock worth $659,000 after buying an additional 169,387 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Autolus Therapeutics by 74.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,531,688 shares of the company's stock worth $8,810,000 after buying an additional 1,080,897 shares during the last quarter. Finally, Privium Fund Management B.V. lifted its stake in shares of Autolus Therapeutics by 220.9% during the 2nd quarter. Privium Fund Management B.V. now owns 160,639 shares of the company's stock worth $543,000 after buying an additional 110,581 shares during the last quarter. Institutional investors own 72.83% of the company's stock.

Wall Street Analysts Forecast Growth

AUTL has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a "buy" rating and set a $9.00 price target on shares of Autolus Therapeutics in a research report on Monday, November 11th. Redburn Atlantic raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 target price on the stock in a report on Friday, November 15th. Finally, The Goldman Sachs Group raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and lifted their price target for the company from $7.00 to $7.60 in a report on Monday, November 18th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $10.15.

Autolus Therapeutics Stock Performance

Shares of NASDAQ AUTL traded down $0.15 during midday trading on Wednesday, reaching $3.05. The stock had a trading volume of 1,306,029 shares, compared to its average volume of 1,464,952. The firm has a market cap of $811.57 million, a price-to-earnings ratio of -2.52 and a beta of 1.98. Autolus Therapeutics plc has a twelve month low of $2.69 and a twelve month high of $7.45. The company's 50 day moving average price is $3.71 and its 200 day moving average price is $3.90.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.10). During the same period in the previous year, the business posted ($0.26) EPS. Equities analysts forecast that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.